Equibles does not estimate personal net worth.
Get an email with a short summary when Teva Pharmaceutical Industries Ltd publishes a filing, an earnings call transcript or a press release.
Get TEVA alertsRichard Francis is recorded as Board Member at Teva Pharmaceutical Industries Ltd (TEVA) since January 1, 2023 and CEO at Teva Pharmaceutical Industries Ltd (TEVA). The newest filing on record that lists Richard Francis as CEO and Board Member at Teva Pharmaceutical Industries Ltd (TEVA) is dated March 31, 2026. Teva Pharmaceutical Industries Ltd reported in an 8-K filed November 21, 2022 that Richard Francis was appointed President and Chief Executive Officer, effective January 1, 2023. The proxy statement of Teva Pharmaceutical Industries Ltd reports total compensation of $19,168,709 for Richard Francis in fiscal 2025, including a base salary of $1,700,000. Disclosed compensation is on record for 3 fiscal years. Richard Francis has spoken on 11 earnings calls and 7 other investor events across 1 company, most recently for Teva Pharmaceutical Industries Ltd on October 9, 2026. Teva Pharmaceutical Industries Ltd is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Teva Pharmaceutical Industries Ltd includes Eli Kalif (CFO), Amir Weiss (Chief Accounting Officer), Andrew Weil (Chief Accounting Officer) and 5 others.
“On November 21, 2022, Teva Pharmaceutical Industries Ltd. (the “Company”) announced that its Board of Directors had appointed Richard Francis to become the Company’s President and Chief Executive Officer, effective January 1, 2023.”
“On the call today will be Eric Hughes, head of R&D Chief Medical Officer, and then for the Q&A, I will be joined by Chris Fox, EVP, our Executive Vice President of U.S. Commercial, and Eddie Khalif, Chief Financial Officer.”
“I mean, the capital allocation for in-licensing and BD will be predominantly innovative. It will be predominantly in CNS neurology and more specifically, if we can, in and around the areas we operate, psychiatry, for example, movement disorders, things like that.”
“I mean, the capital allocation for in-licensing and BD will be predominantly innovative. It will be predominantly in CNS neurology and more specifically, if we can, in and around the areas we operate, psychiatry, for example, movement disorders, things like that.”
“That's a question we could spend 45 minutes talking about, but I'll try and make it as succinct as possible. And I think if I just pick some sort of simple headlines is, so when we started this, and probably the reason you didn't cover us back then was we were a pure play generics company.”
“I'll try and be brief, because obviously I could spend the whole time talking about that. So where we are in the story, to answer that first part of the question.”
2023-01-01–present
Last confirmed March 31, 2026
Start not stated–present
Last confirmed March 31, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Teva Pharmaceutical Industries Ltd (TEVA) | President and Chief Executive Officer | $1,700,000 | $19,168,709 |
| 2024 | Teva Pharmaceutical Industries Ltd (TEVA) | President and Chief Executive Officer | $1,600,000 | $15,518,947 |
| 2023 | Teva Pharmaceutical Industries Ltd (TEVA) | President and Chief Executive Officer | $1,600,000 | $25,706,880 |
